Physical Address
Indirizzo: Via Mario Greco 60, Buttigliera Alta, 10090, Torino, Italy
Saidal will build three production units in the wilayas of Ouled Djellal, Ouargla and Tamanrasset
Saidal will build three production units in the wilayas of Ouled Djellal, Ouargla and Tamanrasset
The Minister of the Pharmaceutical Industry, Ouacim Kouidri, assured the National People’s Assembly (APN) on Thursday that several strategic projects, currently in progress, should come into service by the end of 2026. Which will then mark, he said, a qualitative evolution for the pharmaceutical industry in Algeria.
Speaking during an oral question session at the National People’s Assembly (APN), chaired by Toufik Guezout, vice-president of the APN, in the presence of the Minister of Relations with Parliament, Nadjiba Djilali, the minister indicated that the public group Saidal plans to create new manufacturing units for pharmaceutical products in three (3) wilayas in the South, as part of a national strategy aimed at strengthening the pharmaceutical industry. “The public group Saidal planned to create new manufacturing units for pharmaceutical products in Ouled Djellal, Ouargla and Tamanrasset,” said Ouacim Kouidri.
In coordination with the Algerian Investment Promotion Agency (AAPI), he continued, we are working to encourage the establishment of projects in the interior wilayas, the new wilayas and those in the South, where land intended for investment is available, with the aim of creating jobs for the benefit of the inhabitants of these regions. “This initiative, part of the national strategy for the development of the pharmaceutical sector, aims to strengthen local production of medicines and stimulate investment in the south of the country,” he noted.
This approach, he continued, is part of the group’s strategy aimed at carrying out some of its projects in the southern wilayas, as well as within the framework of the action plan for the pharmaceutical industry sector, which is based on strengthening the production of raw materials used in the manufacture of medicines, in particular those intended for the treatment of diabetes, cancer and heart diseases, as well as antibiotics.
Last Tuesday, Ouacim Kouidri assured that the import bill for medicines has been reduced significantly, from 1.25 billion dollars in 2022 to 515 million in 2024, thanks to the rise in local production. This trend is expected to continue in 2025, as part of the measures taken to strengthen the country’s pharmaceutical sovereignty. “233 pharmaceutical establishments are identified today nationally, including 138 specialized in the production of medicines, which cover nearly 82% of national needs.
The hospital market is not left out, since 24% of medicines intended exclusively for hospitals – or 256 out of a total of 1079 – are now manufactured locally,” he indicated. It was during the presentation of a presentation on the national strategy of the sector before the Committee on Economic Affairs, Development, Industry, Trade and Planning of the APN.
Rabah Mokhtari